Document is current
Any future updates will be listed below
-
Authors
Hill, Alison R.
Gbesemete, Diane F.
Coutinho, Tyween
Ibrahim, Muktar
Laver, Jay R.
Goldstein, Peter
Noviello, Stephanie
Rubin, Keith
Faust, Saul N.
Locht, Camille
Read, Robert C.
Dale, Adam P.
-
Funding
Funding for this research was provided by:
ILiAD Biotechnologies, Weston, Florida, USA
- License Information
-
More Information
Article History
Received: 29 December 2025
Accepted: 4 April 2026
First Online: 18 April 2026
Competing interests
: P.G., S.N. and K.R. are employees and equity holders of ILiAD Biotechnologies. C.L. holds patents on the BPZE1 vaccine, which is licensed to ILiAD Biotechnologies, and reports consulting fees from and is an equity holder of ILiAD Biotechnologies. R.C.R., A.D. and J.R.L. received grant funding from ILiAD Biotechnologies paid to their institution to support the conduct of the original clinical trial (no personal payments). S.N.F. received grants/contracts/consulting fees paid to his institution (no personal payments) from ILiAD Biotechnologies, Pfizer, Sanofi, GSK, J&J, Merck, AstraZeneca, Valneva, Moderna, BioNTech, MSD and Medimmune. All other authors declare no competing interests.
